Painless Sharp Wound Debridement With Lidocaine-23%-Tetra-caine-7% Gel Versus EMLA 5% Cream: a Single-blind, Crossover, Randomised, Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Objective: We want to show that IMP 2 (lidocaine-23%-tetracaine-7% gel) is more effective in pain reduction than IMP 1 (EMLA® 5% cream) in sharp wound debridement.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Participants between 18 years and 90 years

• Chronic leg ulcer(s) (duration \> 4 weeks) with biofilm or necrotic layers which require consecutive sharp debridement for at least two times (of the same ulcer)

• Minimal ulcer area of 1 cm2

• Leg ulcer has to enter into one of the following well defined aetiologies: venous, mixed venous-arterial, arterial, hypertensive ischemic leg ulcer (Martorell), vasculitic, ecthyma (covering \>90% of all observed leg ulcers)

• Informed consent as documented by signature and being able to follow the study protocol (cognition)

• Proficiency in German, oral and written information

Locations
Other Locations
Switzerland
Department of Dermatology, University Hospital of Zurich, Switzerland
RECRUITING
Zurich
Contact Information
Primary
Juerg Hafner, Prof.
juerg.hafner@usz.ch
+41 44 255 25 33
Time Frame
Start Date: 2023-06-01
Estimated Completion Date: 2023-12-31
Participants
Target number of participants: 40
Treatments
Experimental: IMP2 (lidocaine-23%-tetracaine-7% gel)
Active_comparator: IMP1 (EMLA 5% cream)
Related Therapeutic Areas
Sponsors
Leads: Juerg Hafner

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.